Synthesis and microbiological activity of some N-(o-hydroxyphenyl)benzamides and phenylacetamides as the possible metabolites of antimicrobial active benzoxazoles: part II

Antifungal Activity of New Eugenol-Benzoxazole Hybrids against Candida spp.

“…The data from spectrometric analysis of intermediates 2, 2 , 3, and 3 showed perfect agreement with those found in the literature [18]. Following, these aminophenols were converted to N-(o-hydroxyphenyl)benzamides by acylation in mild conditions with appropriate carboxylic acid chlorides in an ice-cooled mixture of ether-water and sodium bicarbonate [19]. The benzamides 4a-4d and 4a -4d were obtained in excellent yields after filtration or solvent extraction.…”

Pharmacological Potential of Benzamide Analogues and their Uses in Medicinal Chemistry

“…It has been suggested that activators of β cell K ATP channels can be used in the treatment of metabolic diseases through an inhibition of insulin release to induce β cell rest. The 2-(4-methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl) benzamides (Schemes 35-43), its close analogues as an activator of Kir6.2/SUR/K ATP channels of β cells and inhibit glucose stimulated insulin release [25][26][27].…”

Synthesis, in silico and in vitro anti-proliferative studies of some novel benzamido substituted imidazo[1,2-b]pyridazin-2-ones

“…The inhibitory activity of these drugs on B-Raf kinase [11,12] revealed that the substituted benzene sulphonamido group is important for inhibitory activity. On the other hand the molecular entities possessing Heterocyclic/ non heterocyclic and substituted/unsubstituted benzamides have been well investigated to possess antimicrobial [13][14][15][16][17][18][19][20], analgesic, anti-inflammatory [21,22], anticonvulsant [23][24][25][26][27][28], anticancer [29][30][31][32][33], and other biological activities [34][35][36][37][38][39][40][41] and imidazopyridazines being structural analogues of purines were also reported to be promising scaffolds exhibiting a wide range of biological activities [42][43][44][45][46]. In view of these reports, our interest moved to develop new benzamido substituted scaffolds which are isosteric analogs of sulphonamido substituted marketed drugs as possible B-Raf Kinase inhibitors and are expected to acquire different selectivities and novelties.…”